FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084388049> ?p ?o ?g. }

• W2084388049 endingPage "181" @default.
• W2084388049 startingPage "176" @default.
• W2084388049 abstract "Summary Objective Central hyperthyroidism is mainly due to two different causes, TSH‐secreting pituitary adenoma (TSH‐oma) and resistance to thyroid hormone in its pituitary variant, i.e. patients presenting with signs and symptoms of hyperthyroidism (PRTH). Because therapeutic approach and the clinical follow‐up are extremely different in these two disorders, a correct differential diagnosis is mandatory. Unfortunately, no definite pathognomonic tool is presently available and an extensive biochemical and instrumental workup is frequently needed in order to reach the correct diagnosis. Aim of the present study was to investigate the use of somatostatin analogues in the differential diagnosis between TSH‐omas and PRTH, as well as the possible treatment of PRTH with these analogues. Design and Patients Eight patients with TSH‐oma and four with PRTH underwent the acute test with somatostatin analogue Octreotide (0·1 mg subcutaneously), as well as long‐acting Octreotide‐LAR (30 mg intramuscularly every 28 days) for two months. Measurements Serum TSH, FT3 and FT4 were evaluated in basal condition, at time 0 and every hour for 6 h during acute test, and every 15 days for 2 months during chronic treatment. Results During acute test, in both patients with PRTH and TSH‐oma, a similar reduction in immunoreactive TSH and FT3 levels was observed, while no variations were found in FT4 concentrations. In contrast, during the administration of Octreotide‐LAR, no significant variations of all tested parameters were observed in PRTH group, whereas FT3 and FT4 concentrations normalized or presented a significant reduction (> 30% of pretreatment values) in seven of eight patients with TSH‐oma, despite minor variation of immunoreactive TSH levels. Conclusions Chronic administration of long‐acting somatostatin analogues in patients with central hyperthyroidism caused a marked decrease of FT3 and FT4 levels in all patients but one with TSH‐oma, while patients with PRTH did not respond at all. Thus, administration of long acting somatostatin analogues for at least 2 months can be useful in the differential diagnosis in problematic cases of central hyperthyroidism. Furthermore, the present findings exclude the possibility of a beneficial effect of chronic administration of somatostatin analogues in controlling thyrotoxic symptoms in PRTH patients." @default.
• W2084388049 created "2016-06-24" @default.
• W2084388049 creator A5026736731 @default.
• W2084388049 creator A5032827403 @default.
• W2084388049 creator A5041064460 @default.
• W2084388049 creator A5055032010 @default.
• W2084388049 creator A5055208154 @default.
• W2084388049 creator A5072279218 @default.
• W2084388049 creator A5077613101 @default.
• W2084388049 creator A5089944760 @default.
• W2084388049 date "2004-12-23" @default.
• W2084388049 modified "2023-10-15" @default.
• W2084388049 title "Different responses to chronic somatostatin analogues in patients with central hyperthyroidism" @default.
• W2084388049 cites W1514507967 @default.
• W2084388049 cites W1517790462 @default.
• W2084388049 cites W1968641918 @default.
• W2084388049 cites W1973610322 @default.
• W2084388049 cites W1986871408 @default.
• W2084388049 cites W1989522103 @default.
• W2084388049 cites W2004357951 @default.
• W2084388049 cites W2010339794 @default.
• W2084388049 cites W2029038788 @default.
• W2084388049 cites W2029647014 @default.
• W2084388049 cites W2051024047 @default.
• W2084388049 cites W2054825056 @default.
• W2084388049 cites W2054952056 @default.
• W2084388049 cites W2068143271 @default.
• W2084388049 cites W2090928881 @default.
• W2084388049 cites W2104955808 @default.
• W2084388049 cites W2136303773 @default.
• W2084388049 cites W2145971304 @default.
• W2084388049 cites W2147367493 @default.
• W2084388049 cites W2150435178 @default.
• W2084388049 cites W2163960934 @default.
• W2084388049 cites W4230589991 @default.
• W2084388049 cites W4233076835 @default.
• W2084388049 cites W4240405995 @default.
• W2084388049 cites W4244392180 @default.
• W2084388049 cites W4244410666 @default.
• W2084388049 cites W4245546571 @default.
• W2084388049 cites W4253029746 @default.
• W2084388049 cites W2055042422 @default.
• W2084388049 doi "https://doi.org/10.1111/j.1365-2265.2004.02192.x" @default.
• W2084388049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15670193" @default.
• W2084388049 hasPublicationYear "2004" @default.
• W2084388049 type Work @default.
• W2084388049 sameAs 2084388049 @default.
• W2084388049 citedByCount "81" @default.
• W2084388049 countsByYear W20843880492012 @default.
• W2084388049 countsByYear W20843880492013 @default.
• W2084388049 countsByYear W20843880492014 @default.
• W2084388049 countsByYear W20843880492015 @default.
• W2084388049 countsByYear W20843880492016 @default.
• W2084388049 countsByYear W20843880492017 @default.
• W2084388049 countsByYear W20843880492018 @default.
• W2084388049 countsByYear W20843880492019 @default.
• W2084388049 countsByYear W20843880492020 @default.
• W2084388049 countsByYear W20843880492021 @default.
• W2084388049 countsByYear W20843880492022 @default.
• W2084388049 countsByYear W20843880492023 @default.
• W2084388049 crossrefType "journal-article" @default.
• W2084388049 hasAuthorship W2084388049A5026736731 @default.
• W2084388049 hasAuthorship W2084388049A5032827403 @default.
• W2084388049 hasAuthorship W2084388049A5041064460 @default.
• W2084388049 hasAuthorship W2084388049A5055032010 @default.
• W2084388049 hasAuthorship W2084388049A5055208154 @default.
• W2084388049 hasAuthorship W2084388049A5072279218 @default.
• W2084388049 hasAuthorship W2084388049A5077613101 @default.
• W2084388049 hasAuthorship W2084388049A5089944760 @default.
• W2084388049 hasConcept C126322002 @default.
• W2084388049 hasConcept C134018914 @default.
• W2084388049 hasConcept C142724271 @default.
• W2084388049 hasConcept C2776216936 @default.
• W2084388049 hasConcept C2776297358 @default.
• W2084388049 hasConcept C2776407475 @default.
• W2084388049 hasConcept C2778024521 @default.
• W2084388049 hasConcept C2779134260 @default.
• W2084388049 hasConcept C2779306644 @default.
• W2084388049 hasConcept C2780801072 @default.
• W2084388049 hasConcept C2781025020 @default.
• W2084388049 hasConcept C2910487530 @default.
• W2084388049 hasConcept C4134927 @default.
• W2084388049 hasConcept C71315377 @default.
• W2084388049 hasConcept C71924100 @default.
• W2084388049 hasConcept C90924648 @default.
• W2084388049 hasConceptScore W2084388049C126322002 @default.
• W2084388049 hasConceptScore W2084388049C134018914 @default.
• W2084388049 hasConceptScore W2084388049C142724271 @default.
• W2084388049 hasConceptScore W2084388049C2776216936 @default.
• W2084388049 hasConceptScore W2084388049C2776297358 @default.
• W2084388049 hasConceptScore W2084388049C2776407475 @default.
• W2084388049 hasConceptScore W2084388049C2778024521 @default.
• W2084388049 hasConceptScore W2084388049C2779134260 @default.
• W2084388049 hasConceptScore W2084388049C2779306644 @default.
• W2084388049 hasConceptScore W2084388049C2780801072 @default.
• W2084388049 hasConceptScore W2084388049C2781025020 @default.
• W2084388049 hasConceptScore W2084388049C2910487530 @default.
• W2084388049 hasConceptScore W2084388049C4134927 @default.

• next